Please login to the form below

Not currently logged in
Email:
Password:

Philippe Calais appointed CEO of Antisense Pharma

Joins as German biopharma aims to take cancer drug trabedersen to phase I

Philippe Calais - AntisenseDr Philippe Calais has joined the German biopharma Antisense Pharma as CEO.

Dr Calais replaces interim CEO Dr Hubert Heinrichs, who has held the position in addition to his role as chief medical officer since July, 2011.

One of his main tasks will be to ensure funding for the development of cancer drug trabedersen, which is planned to start phase I studies as a second-line treatment of pancreatic cancer.

“With Dr Calais, Antisense Pharma has gained an experienced global player in the pharmaceutical sector for its management board,” said Dr Heinrichs.

“During his professional career, he has been actively involved in all stages of the development of medicinal products, from discovery to clinical development, registration and commercialisation.”

This experience includes spells at Roche, where he was business unit head strategic marketing, and ICI Pharmaceuticals.

Other previous roles include CEO and president of Ambrilia Biopharma, president of global business at Neurochem and general manager at Servier Canada.

His most recent position was president and CEO of Canada-based Univalor.

“I am proud and honoured to join Antisense Pharma to lead the company's efforts in the new strategic direction,” Dr Calais commented. “Trabedersen's development package convinced me of the value of this drug candidate as I see its great potential in the fight against aggressive tumours.”

18th May 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics